Number of participants with increased pain after 4 weeks · patients with pain in Guillain‐Barré syndrome
Methylprednisolone showed no clear difference in number of participants with increased pain after 4 weeks compared with placebo (low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes pain score (numerical rating scale of 0 to 10: 0 = no pain, 10 =… compared with placebo (very low certainty).
1 finding from 1 review
Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes sedation score (numerical rating scale of 1 to 6: 0 = anxious,… compared with placebo (very low certainty).
1 finding from 1 review
Rescue analgesic consumption · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes rescue analgesic consumption compared with placebo (very low certainty).
1 finding from 1 review
Nausea · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes nausea compared with placebo (very low certainty).
1 finding from 1 review
Constipation · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes constipation compared with placebo (very low certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · patients with pain in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with pain in Guillain‐Barré syndrome
1 finding from 1 review
Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · patients with pain in Guillain‐Barré syndrome
1 finding from 1 review
Death ‐ at 180 days after ICU admission, in total population randomised · critically ill patients
Corticosteroids showed no clear difference in death ‐ death at 180 days in total population randomised compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ shock · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ shock compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ serious infection · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ serious infection compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ suspected or probable pneumonia · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ suspected or probable… compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (continuous data) ‐ blood glucose (mg/dL) on day 7 · critically ill patients
1 finding from 1 review
Occurrence of CIP/CIM ‐ in the total population randomised · critically ill patients
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in total population randomised compared with placebo compared (low certainty).
1 finding from 1 review
Occurrence of CIP/CIM ‐ in screened population · critically ill patients
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in screened population compared with placebo compared (moderate certainty).
1 finding from 1 review
Improved muscle function various methods1 · people with myasthenia gravis
1 finding from 1 review
no estimate extracted
10 participants
Very low
Adverse events · people with myasthenia gravis
1 finding from 1 review
Change in impairment 1 to 14 days after the start of treatment ‐ not reported · people with myasthenia gravis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reduction in fatigue · people with fatigue in Guillain‐Barré syndrome
Amantadine showed no clear difference in reduction in fatigue of at least 1‐point on the Fatigue Severity… compared with placebo (low certainty).
1 finding from 1 review
OR 0.56 [0.22, 1.35]
74 participants
Low